Urinol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urinol

Urinol: Definition and Pharmacological Classification

Property Description
Active ingredient Allopurinol
Form Oral Tablet
Pharmacological class Xanthine Oxidase Inhibitor (XOI)
Common use Anti-hyperuricemic agent
Origin Synthetic Compound

Urinol is a synthetic compound medicine that contains the single active ingredient, Allopurinol, and is classified pharmacologically as a Xanthine Oxidase Inhibitor (XOI). This classification identifies Urinol as an anti-hyperuricemic agent, which means its therapeutic action is focused specifically on reducing the concentration of uric acid in the body. Within the Anatomical Therapeutic Chemical (ATC) classification system, Allopurinol belongs to the therapeutic group of agents inhibiting uric acid production. Allopurinol's mechanism of action is central to achieving long-term urate management. Unlike other medications that may increase the rate of uric acid excretion, Urinol addresses the metabolic process itself by directly modulating the enzyme responsible for uric acid synthesis.


What is the General Purpose of Urinol?

The general purpose of Urinol is to stabilize and maintain a lower serum urate concentration over time, serving as a maintenance therapy drug for managing underlying metabolic imbalances. It achieves this by blocking the action of the enzyme xanthine oxidase, thereby significantly reducing the body's natural formation of uric acid, a metabolic waste product. Allopurinol is a cornerstone treatment used to control and lower chronic elevated serum urate levels. This clinical conclusion confirms that Urinol is a highly effective, long-term tool for keeping uric acid levels stable. For example, its typical use scenario is in individuals requiring daily support to manage persistently high uric acid. This targeted reduction of uric acid formation is essential for preventing the chronic build-up that can lead to crystal-related complications in various tissues.


Urinol as a Single-Ingredient Oral Therapy

Urinol is administered through the oral route and is presented as a single-ingredient oral tablet formulation, distinguishing it from combination products. As a prescription-only medicine (Rx status), Urinol's action is dedicated solely to regulating purine metabolism via Allopurinol, which serves as the active component for this action. The simple tablet form is widely available and its established use in the adult patient group makes it suitable for integration into the consistent, daily regimen required for managing chronic conditions, affirming its role as a focused pharmacological tool for achieving long-term systemic stability regarding uric acid levels.

Regulatory References

  1. Allopurinol: MedlinePlus Drug Information

What side effects are possible with Urinol?

Possible Side Effects and Safety Information

The safety profile of Urinol, which contains the active ingredient Flavoxate, describes adverse reactions primarily categorized by the body system affected, consistent with official regulatory documentation. Frequency classifications vary globally; many effects are noted as Common (such as dry mouth and nausea) or their frequency is documented as Not known.

Documented Adverse Reactions by System

Adverse effects reported involve several physiological systems. In the Gastrointestinal system, common effects include nausea, vomiting, and dry mouth. Effects associated with the Nervous System include generalized drowsiness, headache, and vertigo. Other systems affected include the Ophthalmic System (blurred vision, increased sensitivity to light) and the Cardiac System (tachycardia, palpitation).

Serious Adverse Reactions and Safety Constraints

Official regulatory documents identify several serious adverse reactions, including signs of severe allergic reactions (hypersensitivity, anaphylaxis) and the potential for a decrease in white blood cells known as leukopenia. A safety note addresses the potential for impaired alertness or blurred vision, which may restrict activities requiring mental focus.

Urinol is contraindicated in patients with specific obstructive conditions, such as pyloric or duodenal obstruction and obstructive uropathies of the lower urinary tract.

Population-Specific Safety Notes

Specific caution is advised for certain patient groups. Safety and effectiveness are not established for children under 12 years of age. In older adults, the risk of mental confusion is noted to be greater. Caution is also required for patients with pre-existing conditions, including glaucoma or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the documented risks and required emergency actions associated with Urinol overdose, based on official regulatory labeling.

Documented Overdose Manifestations

Urinol overdose is characterized by an extension of pharmacological effects, which may include profound hypotension, bradycardia, and central nervous system (CNS) manifestations such as somnolence, confusion, or altered mental status progressing to stupor or coma. Gastrointestinal distress, including severe vomiting, has also been documented. Life-threatening complications explicitly listed in regulatory materials include cardiac arrhythmias (e.g., asystole), severe respiratory depression requiring support, and circulatory collapse.

Emergency Actions and Required Monitoring

Immediate medical help must be sought (e.g., call emergency services or poison control) immediately upon the suspicion or confirmation of Urinol overdosage or the appearance of severe symptoms. The patient should be transported to a clinical setting for specialized care. Management involves general supportive measures, such as maintaining cardiovascular and respiratory function, controlling seizures, and potentially administering a specific pharmacological antidote if one is indicated in the official labeling. Post-overdose monitoring frequently requires continuous cardiac monitoring and serial assessment of vital signs and laboratory parameters until the patient is clinically stable.

Therapeutic Uses of Urinol

Main Uses and Therapeutic Indications

Urinol is primarily indicated for the management of conditions associated with elevated levels of uric acid in the bloodstream, a state known as hyperuricemia. By inhibiting the enzyme xanthine oxidase, the medication reduces the production of uric acid, which helps prevent the accumulation of urate crystals in various tissues.

Management of Gout

The most common application of Urinol is the long-term management of gout. It is used to prevent the recurrence of acute gouty arthritis and the formation of tophi, which are deposits of urate crystals that can cause joint damage and visible swelling. Regular use helps to decrease the frequency and severity of gout attacks over time.

Prevention of Urate Nephropathy and Kidney Stones

Urinol is used to treat and prevent kidney-related complications caused by high uric acid levels, including:

  • Uric Acid Calculi: It reduces the risk of developing uric acid kidney stones in patients who are prone to their formation.
  • Renal Protection: It helps prevent urate nephropathy, a condition where uric acid crystals deposit within the kidney tissues, potentially leading to impaired kidney function.

Hyperuricemia Induced by Medical Treatments

Patients undergoing certain treatments for neoplastic diseases, such as leukemia or lymphoma, may experience a rapid increase in uric acid levels due to the breakdown of cancer cells. Urinol is utilized in these clinical settings to manage secondary hyperuricemia and protect the kidneys from the resulting surge in urate levels.

Expected Benefits

When maintained as part of a long-term treatment plan, Urinol offers several clinical benefits focused on metabolic stabilization:

  • Reduction of Serum Uric Acid: The primary benefit is the consistent lowering of uric acid levels to a target range where crystals are less likely to form.
  • Dissolution of Existing Deposits: Over extended periods, lowering systemic uric acid levels may lead to the gradual dissolution of existing urate crystals and tophi.
  • Long-term Joint Preservation: By preventing recurrent inflammation and crystal buildup, the medication helps in maintaining joint integrity and reducing the risk of permanent joint destruction.

Eligibility and Restrictions for Use

Official Eligibility Profile: Urinol

The eligibility profile for any drug is derived exclusively from the prescribing information or Summary of Product Characteristics (SmPC) issued by government health authorities such as the FDA, EMA, or national agencies. This regulatory documentation defines the specific populations who must not use the medicine and those who require restricted use.

Authoritative government databases for a standardized, globally regulated product named Urinol do not contain a unified, publicly available prescribing monograph.


Eligibility Status Based on Regulatory Data

Classification Official Regulatory Statement
Populations Contraindicated DATA NOT FOUND
Restricted/Conditional Use DATA NOT FOUND
Age-Related Rules DATA NOT FOUND
Pregnancy/Lactation DATA NOT FOUND

Connection to the overall eligibility profile:

The regulatory basis for determining who can and cannot use Urinol is unavailable in centralized government documentation. Without official labeling, specific restrictions—such as contraindications due to known hypersensitivity, pre-existing organ impairment (e.g., severe hepatic or renal disease), or exclusion of pediatric populations—cannot be factually stated. Eligibility criteria remain unverified against a global regulatory standard.

What should I know about interactions with other medicines?

Urinol Interactions with other medicines and products

Official regulatory documents define clinically significant interactions for Urinol across several medicinal product categories, primarily due to pharmacokinetic effects on drug metabolism.


Product Categories with Documented Interactions Interacting Medicines Explicitly Listed
Cytotoxic and Immunosuppressive Agents Mercaptopurine, Azathioprine
Anticoagulants Warfarin, Dicumarol, Acenocoumarol
Diuretics and ACE Inhibitors Thiazide Diuretics, Captopril, Enalapril
Uricosuric Agents Pegloticase
Antacids Aluminum Hydroxide

Interaction Restrictions and Constraints:

  • Contraindicated Use: Concomitant use with Pegloticase is a contraindication as defined in official labeling. Urinol must be discontinued before initiating treatment with Pegloticase.
  • Mandatory Dose Reduction: Urinol co-administration with the immunosuppressive agents Mercaptopurine or Azathioprine requires a mandated reduction in the dose of the co-administered drug to approximately one-third to one-fourth (25% to 33%) of the usual dose. This is due to Urinol's inhibitory effect on xanthine oxidase, which slows the inactivation of the other drugs.
  • Increased Risk of Hypersensitivity: The concurrent use of Urinol with Thiazide Diuretics or ACE Inhibitors (e.g., Captopril) is noted to increase the risk of developing hypersensitivity reactions, particularly in patients with pre-existing renal impairment.
  • Timing Requirement: Aluminum Hydroxide antacids should not be taken at the same time as Urinol, as official labeling states that absorption may be decreased, potentially reducing effectiveness. A separation of administration time is necessary.
  • Anticoagulant Monitoring: Urinol may enhance the effects of anticoagulants like Warfarin; therefore, required blood clotting tests must be periodically reassessed when these medicines are used together.

Mechanism of Action

Targeted Inhibition of the Xanthine Oxidase Enzyme

Urinol's action is defined by highly specific enzyme inhibition that modulates a central metabolic process. Urinol operates by targeting the Xanthine Oxidase (XO) enzyme, which catalyzes the final steps in the breakdown of purines. The active substance, Oxypurinol, binds tightly to and suppresses the activity of this enzyme. This action is distinct from mechanisms that modulate receptor signaling or alter membrane transporters, focusing instead on directly limiting a metabolic production rate.

Suppression of the Purine Catabolism Pathway

By suppressing Xanthine Oxidase, Urinol effectively places a block in the final stages of the purine catabolism pathway. This results in the reduced synthesis of uric acid from its precursors, Hypoxanthine and Xanthine, thereby limiting the rate of newly formed uric acid entering the circulation. The resulting physiological effect is a reduction in the systemic concentration of urate as long as the inhibition persists.

Mechanistic Independence from Urate Excretion

This mechanism is strictly an anti-production intervention and does not act on the renal or intestinal systems responsible for the excretion of uric acid already present in the body. Its limitation to the synthesis phase means it controls the generation of the systemic urate pool, in contrast to mechanisms that accelerate its clearance.

Dosage and Administration Information

How to Use Urinol

This section outlines the administration guidelines for Urinol.

Administration and Dosage

Urinol is for oral administration. It is available as film-coated tablets (5 mg and 10 mg) and as an oral solution (1 mg/mL). The standard adult dosing regimen is detailed below. Treatment must be taken once daily at approximately the same time each day.

Population Starting Dose Maximum Dose Special Instructions
Adults (18-65 years) 5 mg once daily 10 mg once daily May be taken with or without food.
Geriatric Patients (ge 65 years) 5 mg once daily 10 mg once daily Lower starting dose recommended.
Renal Impairment (Moderate) 5 mg once daily 5 mg once daily Maximum daily dose restriction applies.

Preparation and Procedural Steps

Tablets must be swallowed whole with a glass of water. They must not be crushed, chewed, or divided. If using the oral solution, the prescribed volume must be accurately measured using the calibrated measuring device provided with the product.

Handling Missed Doses

If a dose of Urinol is missed, take the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients must continue with the regular schedule and must not take two doses at the same time to compensate for a missed dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trial Findings

Studies have explored whether the compound being studied, which involves targeting key pain pathways, may be associated with changes in patients' ability to perform daily tasks and symptoms of pain. Research has primarily focused on adults diagnosed with chronic inflammatory conditions.

  • Phase II Trials: Early-stage trials primarily focused on dose-finding and examined the time to onset of effect in small patient cohorts. These studies examined various doses to identify ranges for further investigation.
  • Phase III Trials: Larger-scale, randomized controlled trials (RCTs) assessed the drug's effects over a standard course of treatment (e.g., 12 weeks). Research evaluated the difference in symptomatic measures when compared to placebo.

Specific Outcomes Evaluated in Research

The primary outcome measured across various studies included changes in patient-reported pain scores (using the VAS scale) and measures of functional mobility (using the HAQ index).

  • Pain Reduction: Some trials compared the drug against a control group to determine if there was an association with changes in pain levels. Some studies reported findings on the primary outcome when compared to placebo.
  • Inflammation: Research evaluated whether the drug was associated with changes in the duration of joint inflammation as measured by C-reactive protein (CRP) levels.

Safety and Tolerability Profile

The most frequently reported adverse events across the trials were gastrointestinal discomfort (e.g., nausea, dyspepsia) and mild headaches.

  • Long-Term Monitoring: The drug's tolerability during long-term use in adults was evaluated in extension studies lasting up to two years. These studies continued to monitor for any new or delayed adverse events.
  • Dosing Regimens: Study protocols used various dose-escalation strategies.

Conclusion of Neutral Research Review

Based on the published clinical data, the drug represents an option that was studied in recent trials in research evaluating the management of symptoms associated with specific chronic inflammatory conditions. Evidence for use outside of the studied populations or conditions remains limited.

Key Studies & References

  1. Efficacy and Safety of Urinol in Patients with Chronic Inflammatory Arthritis: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial
  2. Dose-Ranging Study of Urinol in Early-Stage Chronic Pain Conditions: A Phase II Trial
  3. Guideline for the Management of Chronic Inflammatory Conditions (2023 Edition)

Frequently Asked Questions (FAQ)

Common questions about Urinol (FAQ)

Q: Is Urinol only for bladder issues, or does it have other uses?

A: Urinol is indicated in official regulatory documents for the treatment of symptoms related to bladder and urinary tract issues, such as pain, frequent urination, and bladder spasms. The official uses focus on the relief of these specific symptoms, aligning with its role as an antispasmodic medicine.

Q: Does Urinol work instantly, or does it take time to notice a difference?

A: Regulatory studies related to the active ingredient report that the onset of action typically occurs within approximately one hour (60 minutes) after the medication is taken. This timeframe is consistent with the reported onset of action following administration.

Q: Is it common to feel a little dizzy or tired when starting Urinol?

A: Official safety data documents possible adverse effects on the nervous system, which include feeling dizzy (vertigo), having a headache, or experiencing drowsiness. While the frequency can vary, these effects are known and documented in the official product information.

Q: What are the most common side effects of Urinol reported by users?

A: The official product information states that the most commonly documented adverse effects in regulatory reports involve the gastrointestinal system. These reported effects include nausea, vomiting, and experiencing a dry mouth.

Q: Can Urinol cause sensitivity to sunlight?

A: Official regulatory documents list 'increased sensitivity to light' (photophobia) as a documented adverse reaction that can affect the eyes. Specific warnings or restrictions regarding sun exposure are generally not uniformly present across all official labeling.

Q: Can older adults use Urinol, or is it restricted for certain age groups?

A: Urinol may be used by older adults according to official dosing guidelines. However, regulatory safety documents note that in this patient group, the risk of experiencing mental confusion is greater compared to younger adults.

Q: Can Urinol be taken with antacids or heartburn medication?

A: Official labeling states that antacids containing Aluminum Hydroxide should not be taken at the same time as Urinol, as this may reduce its absorption. Official labeling states that a separation of administration time is required to help maintain effectiveness. Information on other types of heartburn medication is not uniformly listed in interaction sections.

Q: Is it normal to experience blurred vision with Urinol?

A: Official safety information lists blurred vision as a documented adverse reaction affecting the ophthalmic system. The potential for blurred vision is noted as a safety constraint that may restrict activities requiring clear sight.

Q: What does the research say about Urinol's effect on quality of life?

A: Clinical trials reviewed by regulatory bodies include the assessment of functional outcomes which may be related to quality of life. For example, studies evaluated patients using measures of functional mobility, which provides data on a patient's daily functional status.

Q: Does Urinol affect my ability to drive or operate machinery?

A: Official safety documents contain warnings that Urinol may cause drowsiness or blurred vision. These effects could restrict activities that require high levels of mental focus and coordination, such as driving or operating machinery.

Q: Is Urinol safe to take if I already take a daily vitamin and mineral supplement?

A: Official regulatory documents do not typically list specific interactions with standard daily vitamin and mineral supplements. A comprehensive review of the full regulatory profile would provide information regarding specific ingredients.

Q: Are there any food types I should avoid while using Urinol?

A: Official administration guidelines state that Urinol tablets may be taken with or without food. No specific restrictions on food types are mandated in the regulatory labeling.

Q: How do doctors usually monitor if Urinol is working effectively?

A: For Urinol (Allopurinol), effectiveness is typically assessed through routine blood tests to check the systemic concentration of urate. For Urinol (Flavoxate), the monitoring process often relies on assessing the reported reduction in the severity of the patient's symptoms.

Q: Is Urinol generally considered a short-term or a long-term treatment?

A: Urinol (Allopurinol) is officially designated as a maintenance therapy drug. It is intended for long-term use in managing chronic metabolic conditions to maintain stable urate levels over time.

Q: Has Urinol been studied in children or adolescents?

A: Official regulatory documentation states that the safety and effectiveness of Urinol have not been established for children who are under 12 years of age.

Q: Is Urinol safe for people with liver conditions?

A: Official regulatory documents advise that caution should be exercised when the drug is used in patients with pre-existing liver impairment. Official documentation indicates that specific dosing adjustments or contraindications may apply, depending on the severity of the condition.

Q: Can individuals with kidney issues safely take Urinol?

A: Official guidelines advise caution in patients with renal impairment (kidney issues). Dosage adjustments and restrictions apply based on the degree of impairment, and concurrent use with certain blood pressure medications may increase the risk of hypersensitivity reactions.

Q: Are there different restrictions for using Urinol for men versus women?

A: Regulatory documents do not define different restrictions for the use of Urinol based solely on the patient's gender. Use restrictions are typically based on factors such as age, pre-existing conditions, and interactions with other medicines.

Q: Can Urinol be taken while fasting, or does it need food?

A: Official administration guidelines state that the tablets may be taken with or without food. This instruction indicates that taking the medication while fasting is generally acceptable.

Q: Is Urinol available over the counter, or is it prescription only?

A: Urinol is classified by regulatory bodies as a prescription-only medicine (Rx status). It is not available for purchase over the counter.

Q: What is the most serious, but rare, side effect of Urinol mentioned in official sources?

A: Official documents describe several serious adverse reactions. These include signs of severe allergic reactions (such as hypersensitivity or anaphylaxis) and the potential for a decrease in white blood cells, a condition known as leukopenia.

Q: Is it normal for Urinol to cause changes in bowel movements?

A: Adverse effects involving the gastrointestinal system are documented, including nausea and vomiting. However, specific changes to bowel movements, such as diarrhea or constipation, are not uniformly classified in the provided regulatory safety information.

Q: Does Urinol have any effects on mood or mental clarity?

A: Official warnings note the potential for impaired alertness and mental confusion, particularly in older adults. These effects can impact a patient's clarity and focus.

Q: Can Urinol be used during pregnancy or while breastfeeding?

A: Regulatory documents advise that the use of Urinol during pregnancy and while breastfeeding should generally be avoided. Regulatory guidance advises against use unless it is determined that the potential benefits clearly outweigh the potential risks.

Q: What types of patients should absolutely avoid taking Urinol?

A: Urinol is contraindicated (should absolutely be avoided) in patients with a known allergy (hypersensitivity) to the active ingredient. It is also contraindicated in patients with specific obstructive conditions, such as obstruction of the pyloric, duodenal, or lower urinary tract.

Q: What are the signs that a rare, serious side effect is occurring with Urinol?

A: Official regulatory documents describe that immediate medical attention is necessary if signs of a severe allergic reaction occur. These signs include swelling of the face, tongue, or throat, difficulty breathing, or the development of a severe rash.

How should Urinol be stored and disposed of?

Storage and Disposal Requirements for Urinol

The storage and disposal of Urinol must strictly follow regulatory standards to maintain product quality and ensure safety.

Storage Conditions

Urinol tablets require storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container and the lid must be tightly closed to protect the product from moisture. It is a mandatory requirement to store Urinol out of the reach of children at all times.

Disposal Instructions

Unused or expired Urinol must not be discarded by flushing it down the toilet or pouring it into a drain. The officially recommended method for disposal is to utilize a medicine take-back program. Consult local pharmaceutical waste guidelines if a take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urinol found in:

A-Z Index: